Arasid-100/Arasid-500/Arasid-1000 Use In Pregnancy & Lactation

Pregnancy: Cytarabine is known to be teratogenic in some animal species. The use of cytarabine in women who are, or who may become, pregnant should be undertaken only after due consideration of the potential benefits and hazards.
Women have to use effective contraception during and up to 6 months after treatment.
Lactation: This product should not normally be administered to patients who are pregnant or to mothers who are breastfeeding.
Fertility: Fertility studies to assess the reproductive toxicity of cytarabine have not been conducted. Gonadal suppression, resulting in amenorrhea or azoospermia, may occur in patient taking cytarabine therapy, especially in combination with the alkylating agents. In general, these effects appear to be related to dose and length of therapy and may be irreversible (see Adverse Reactions). Given that cytarabine has a mutagenic potential which could induce chromosomal damage in the human spermatozoa, males undergoing cytarabine treatment and their partner should be advised to use a reliable contraceptive method during and up to 6 months after treatment.